Normosang (Human Hemin)

Human hemin provides a source of heme that binds to the transcriptional repressor Bach1 in liver cells, leading to down‑regulation of aminolevulinic acid synthase 1 (ALAS1), the first and rate‑limiting enzyme of the heme biosynthetic pathway. This reduces the synthesis of aminolevulinic acid and porphobilinogen, preventing the buildup of toxic intermediates that trigger acute porphyria attacks.

The dose of Normosang is individualized by the treating physician based on the severity of the acute porphyria attack, patient weight, and laboratory monitoring of porphyrin precursors. The prescribing clinician determines the amount and frequency of intravenous infusion, which is typically administered in a hospital or specialized infusion setting.

Safety data for human hemin in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainties with the patient and consider alternative management strategies when possible.

To request Normosang, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative to human hemin is glucose loading, which can suppress ALAS1 activity through carbohydrate‑induced repression but often provides slower symptom relief. Human hemin delivers a direct heme source, achieving more rapid down‑regulation of porphyrin precursor synthesis and faster clinical improvement, especially in severe attacks. Choice of therapy depends on attack severity, patient tolerance and clinical guidelines.

Normosang must be stored refrigerated at 2–8 °C, protected from light, and should never be frozen or shaken. The solution should be kept in its original packaging until use, and any unused portion must be discarded according to local regulations. Proper cold‑chain handling during transport is essential to maintain product stability.

Normosang is supplied as a sterile solution for injection and is administered intravenously, usually through a peripheral or central venous line. The infusion is performed in a controlled clinical environment, with the rate and duration determined by the prescribing physician. Patients are monitored for vital signs and potential infusion‑related reactions throughout the administration.

The most serious adverse events linked to Normosang include anaphylactic reactions, methemoglobinemia, hemolysis, acute renal failure and thrombophlebitis at the infusion site. Early recognition of symptoms such as sudden shortness of breath, cyanosis, dark urine, decreased urine output or severe pain at the catheter site is critical, and immediate medical intervention should be initiated.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, active infections, or those receiving medications that may provoke severe hemolysis or methemoglobinemia. The decision to use the product should be made by a qualified healthcare professional after evaluating these risk factors.